Raptor Pharmaceutical (RPTP) : 4 analysts are covering Raptor Pharmaceutical (RPTP) and their average rating on the stock is 2, which is read as a Buy. 2 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 2, which recommends a Buy affirms that they expect a large upside in the stock from the current levels. A total of 2 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.
Raptor Pharmaceutical (RPTP) : The highest short term price target forecast on Raptor Pharmaceutical (RPTP) is $10 and the lowest target price is $8. A total of 4 equity analysts are currently covering the company. The average price of all the analysts is $9 with a standard deviation of $0.82.
Also, Equity Analysts at the Citigroup maintains the rating on Raptor Pharmaceutical (NASDAQ:RPTP). The brokerage firm has issued a Neutral rating on the shares. The Analysts at the ratings agency raises the price target from $6 per share to $8 per share. The rating by the firm was issued on August 9, 2016.
Raptor Pharmaceutical (NASDAQ:RPTP): After opening at $8.95, the stock dipped to an intraday low of $8.95 on Thursday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $8.98 and the buying power remained strong till the end. The stock closed at $8.98 for the day, a gain of 0.22% for the day session. The total traded volume was 2,711,765. The stocks close on the previous trading day was $8.96.
Raptor Pharmaceutical Corp. is a biopharmaceutical company. The Company is focused on developing and commercializing transformative treatments for people affected by rare and debilitating diseases. The Companys product, PROCYSBI delayed-release capsules received marketing approval from the FDA for the management of nephropathic cystinosis in adults and children six years and older. In Europe, PROCYSBI gastro-resistant hard capsules of cysteamine, received a marketing authorization from the European Commission (EC), as an orphan medicinal product for the management of nephropathic cystinosis in the European Union (EU). The Companys pipeline includes its delayed-release form of cysteamine, or RP103 and its oral 4-methylpyrazole, or Convivia. Its other product, Quinsair, is an inhaled formulation of levofloxacin used for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.